Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.12 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

urologix inc (ULGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - $0.20
52 Week Low
02/10/15 - $0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UROLOGIX INC (ULGX)

Related News

No related news articles were found.

urologix inc (ULGX) Related Businessweek News

No Related Businessweek News Found

urologix inc (ULGX) Details

Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from benign prostatic hyperplasia (BPH). The company offers Cooled ThermoTherapy product line, which includes the CoolWave and Targis Control Units, and the CTC Advance catheter for the production of targeted microwave energy combined with a unique cooling mechanism to protect healthy urethral tissue and enhance patient comfort. It also distributes Prostiva RF Therapy Systems, which delivers radio frequency energy directly into the prostate and destroys prostate tissue that reduces constriction of the urethra and relieves BPH voiding symptoms. The company distributes its products to urologist offices, ambulatory surgery centers, and hospitals through its direct sales force and local distributors in the United States and internationally. Urologix, Inc was founded in 1991 and is based in Minneapolis, Minnesota.

61 Employees
Last Reported Date: 09/19/14
Founded in 1991

urologix inc (ULGX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $200.0K
Executive Vice President of Sales and Marketi...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2014.

urologix inc (ULGX) Key Developments

Urologix, Inc. Appoints Scott M. Madson as Chief Financial Officer Effective April 1, 2015

Urologix, Inc. announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Mr. Madson will report to the company's Chief Executive Officer, Greg Fluet.

Urologix, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2014

Urologix, Inc. reported unaudited earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported sales of $3,079,000 against $3,806,000 a year ago. Operating loss was $134,000 against $892,000 a year ago. Loss before income taxes was $353,000 against $1,069,000 a year ago. Net loss was $357,000 or $0.02 per diluted share against $1,085,000 or $0.05 per diluted share a year ago. For the six months the company reported sales of $6,100,000 against $7,585,000 a year ago. Operating loss was $375,000 against $2,055,000 a year ago. Loss before income taxes was $785,000 against $2,391,000 a year ago. Net loss was $794,000 or $0.04 per diluted share against $2,419,000 or $0.11 per diluted share a year ago. Net cash used for operating activities was $138,000 against $990,000 a year ago. Purchase of property and equipment was $1,000 against $27,000 a year ago.

Urologix, Inc. Announces Revenue Guidance for Second Quarter Ended on December 31, 2014

Urologix, Inc. announced revenue guidance for its second quarter of fiscal year 2015 ended on December 31, 2014. For the, second quarter of fiscal year 2015 revenue is expected to be approximately $3.1 million, up approximately 2% sequentially from the first quarter of fiscal year 2015. The second quarter revenue was down approximately 19% compared to the second quarter of the prior fiscal year, which was the last full quarter of operations before the Company restructured its sales and operations in the second half of fiscal year 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULGX:US $0.12 USD 0.00

ULGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.88 USD +0.14
Cogentix Medical Inc $1.67 USD +0.06
Medifocus Inc C$0.06 CAD +0.01
Olympus Corp ¥4,320 JPY -20.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ULGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROLOGIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at